ProCE Banner Activity

Key COVID-19 Studies Influencing My Practice Following IDWeek 2022

Slideset Download
Read expert faculty member summaries of the latest data on COVID-19 vaccines, risk factors and risk stratification, diagnostics, therapeutics, treatment of patients with immunocompromise, and long COVID.

Released: November 01, 2022

Share

Faculty

Gregory Huhn

Gregory Huhn, MD, MPHTM

Professor of Medicine
Department of Infectious Diseases
Rush University Medical Center
Interim Chief
Division of Infectious Diseases
Cook County Health
Chicago, Illinois

Princy N. Kumar

Princy N. Kumar, MD

Professor of Medicine and Microbiology
Division of Infectious Diseases
Georgetown University Hospital
Division Chief
Division of Infectious Diseases and Travel Medicine
Department of Internal Medicine
Medstar Georgetown University Hospital
Washington, DC

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp

Faculty Disclosure

Primary Author

Gregory Huhn, MD, MPHTM

Professor of Medicine
Department of Infectious Diseases
Rush University Medical Center
Interim Chief
Division of Infectious Diseases
Cook County Health
Chicago, Illinois

Gregory Huhn, MD, MPHTM: consultant/advisor/speaker: Gilead Sciences, Integritas, Janssen, Lilly, Merck, ViiV; researcher: Gilead Sciences, Janssen, Lilly, ViiV.

Princy N. Kumar, MD

Professor of Medicine and Microbiology
Division of Infectious Diseases
Georgetown University Hospital
Division Chief
Division of Infectious Diseases and Travel Medicine
Department of Internal Medicine
Medstar Georgetown University Hospital
Washington, DC

Princy N. Kumar, MD, FIDSA, MACP: researcher: American Gene Technologies, Gilead Sciences, GlaxoSmithKline, Merck; advisor: Gilead Sciences, Johnson & Johnson, Merck, Theratechnologies, ViiV Healthcare; ownership interest: Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer.